他达拉非治疗射血分数保留心衰合并混合性肺动脉高压的随机对照3期研究
PASSION研究评估他达拉非对射血分数保留心衰合并毛细血管后和毛细血管前肺动脉高压患者的疗效与安全性。因药物供应中断提前终止,共随机125例(安慰剂63例,他达拉非62例)。主要复合终点事件在安慰剂组20例(32%)、他达拉非组17例(27%),风险比1.02(95%CI 0.52-2.01,P=0.95);他达拉非组全因死亡风险可能更高(风险比5.10,95%CI 1.10-23.69,P=0.04)。研究不支持他达拉非用于该人群,并提示潜在安全性问题。
要点
- 他达拉非未改善心衰住院或全因死亡的复合终点(HR 1.02,P=0.95)。
- 他达拉非组全因死亡风险信号更高(HR 5.10,95%CI 1.10-23.69,P=0.04)。
- 研究因药物供应中断提前终止,样本量有限,结论需谨慎解读。
核心结论
- PASSION试验因药物供应中断提前终止,结果不支持他达拉非用于射血分数保留心衰合并毛细血管后和毛细血管前肺动脉高压患者。
- 他达拉非组主要复合终点无获益,且全因死亡风险信号更高,提示潜在安全性问题。
研究设计与样本
- 双盲随机对照3期试验(PASSION),计划纳入372例,因药物供应中断提前终止,实际随机125例(安慰剂63例,他达拉非62例)。
- 研究对象为射血分数保留心衰合并毛细血管后和毛细血管前肺动脉高压患者,1:1随机接受他达拉非目标剂量40 mg或安慰剂。
- 主要终点为裁定心衰住院或全因死亡的首次复合事件时间。
主要发现
- 主要复合终点事件:安慰剂组20例(32%),他达拉非组17例(27%),风险比1.02(95%CI 0.52-2.01,P=0.95)。
- 全因死亡:他达拉非组风险可能更高,风险比5.10(95%CI 1.10-23.69,P=0.04)。
- 其他次要终点(NYHA心功能分级改善或6分钟步行距离较基线改善≥10%)组间无显著差异。
- 严重不良事件:他达拉非组29例(48%),安慰剂组35例(56%)。
临床怎么用
- 不推荐对射血分数保留心衰合并毛细血管后和毛细血管前肺动脉高压患者使用他达拉非。
- 临床决策中应关注他达拉非可能增加全因死亡风险的安全信号。
局限性
- 研究因药物供应中断提前终止,实际样本量125例远低于计划的372例,统计效能不足。
- 提前终止可能影响结果稳定性,全因死亡风险信号基于少数事件,需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We assessed the efficacy and safety of tadalafil, a phosphodiesterase type 5 inhibitor, in patients with heart failure with preserved ejection fraction and combined postcapillary and precapillary pulmonary hypertension. METHODS: In the double-blind PASSION study (Phosphodiesterase-5 Inhibition in Patients With Heart Failure With Preserved Ejection Fraction and Combined Post- and Pre-Capillary Pulmonary Hypertension), patients with heart failure with preserved ejection fraction and combined postcapillary and precapillary pulmonary hypertension were randomized 1:1 to receive tadalafil at a target dose of 40 mg or placebo. The primary end point was the time to the first composite event of adjudicated heart failure hospitalization or all-cause death. Secondary end points included all-cause mortality and improvements in New York Heart Association functional class or ≥10% improvement in 6-minute walking distance from baseline. RESULTS: Initially targeting 372 patients, the study was terminated early because of disruption in study medication supply. At that point, 125 patients had been randomized (placebo: 63; tadalafil: 62,). Combined primary end-point events occurred in 20 patients (32%) assigned to placebo and 17 patients (27%) assigned to tadalafil (hazard ratio, 1.02 [95% CI, 0.52-2.01]; P=0.95). There was a possible signal of higher all-cause mortality in the tadalafil group (hazard ratio, 5.10 [95% CI, 1.10-23.69]; P=0.04). No significant between-group differences were observed in other secondary end points. Serious adverse events occurred in 29 participants (48%) in the tadalafil group and 35 (56%) in the placebo group. CONCLUSIONS: The PASSION trial, terminated prematurely due to study medication supply disruption, does not support tadalafil use in patients with heart failure with preserved ejection fraction and combined postcapillary and precapillary pulmonary hypertension, with potential safety concerns and no observed benefits in primary and secondary end points. REGISTRATION: URL: https://www.clinicaltrialsregister.eu/; Unique identifier: 2017-003688-37. URL: https://drks.de; Unique identifier: DRKS -DRKS00014595.
引用
- Hoeper, Oerke, Wissmüller, et al. Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction: A Randomized Controlled Phase 3 Study. Circulation. 2024. PMID: 38939948. doi:10.1161/CIRCULATIONAHA.124.069340
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。